Iovance Q1 2025 revenue $49.3M; FY2025 guidance revised to $250-300M

IOVANCE BIOTHERAPEUTICS, INC.

2025-Q1 EPS reported -$0.36 revenue$49,324,000

Q1 2025 product revenue $49.3M from Amtagvi ($43.6M) and Proleukin ($5.7M); net loss $116.2M ($0.36 diluted).
FY2025 total product revenue guidance revised to $250-300M reflecting launch dynamics and ATC growth trajectories.
Cash and investments $366M as of March 31, 2025; expected to fund operations into second half of 2026.
Q1 manufacturing capacity reduced by annual maintenance; fully resumed, targeting 100-110 commercial infusions in Q2.
On track for Amtagvi regulatory approvals in UK, EU, Canada in 2025; NSCLC registrational data in 2H25.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.